Kevin Harrington - Reader in Biological Cancer Therapies - Institute of Cancer Research | LinkedIn
Scientific Lecture | Kevin Harrington | FRONTAL
Prof. Kevin Harrington | HSTalks
Kevin HARRINGTON | Institute of Cancer Research, London | Division of Radiotherapy and Imaging | Research profile
Game-changing drug doubles head and neck cancer survival | The Royal Marsden
Kevin Harrington - Reader in Biological Cancer Therapies - Institute of Cancer Research | LinkedIn
Dr. Harrington on the KEYNOTE-048 Trial in Recurrent/Metastatic Head and Neck Cancer
Using Viruses to Treat Cancer | Prof Kevin Harrington | #SCIPEL 2015 | SCI - YouTube
Lapatinib not found to be beneficial in head and neck cancer with high risk of recurrence - ecancer
Professor Kevin Harrington - The Institute of Cancer Research, London
Loop | Kevin Joseph Harrington
Professor Kevin Harrington | The Royal Marsden
Professor Kevin Harrington - The Institute of Cancer Research, London
T-VEC: what's next for oncolytic virotherapy and immuno-oncology? - Oncology Central
Kevin Harrington - Reader in Biological Cancer Therapies - Institute of Cancer Research | LinkedIn
Professor Kevin Harrington to star in BBC2's Trust me, I'm a Doctor - The Institute of Cancer Research, London
Bladder Cancer Survivor Mentors Others with Bladder Cancer | Thrive Fall 2019 | University of Michigan Rogel Cancer Center
Professor Kevin Harrington - YouTube
The ICR på Twitter: "Watch Professor Kevin Harrington on @BBCLondonNews as he shares more on how a modified version of the herpes virus could offer hope for some people with advanced #Cancer.
Will Immunotherapy Put Head and Neck Surgeons Out of Business? – Semon Lectures
Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY
Professor Kevin Harrington - The Institute of Cancer Research, London
Kevin Harrington | Videos & Research | VJOncology
Clinical results, patient cases and future developments II: Head & neck cancer – Kevin Harrington on Vimeo
ESMO Immuno-Oncology Congress 2022 What you can expect - YouTube
SAB and I-O AB - T3 Pharma
